Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

China Pharma Holdings (CPHI) Equity Ratio (2016 - 2025)

Historic Equity Ratio for China Pharma Holdings (CPHI) over the last 17 years, with Q3 2025 value amounting to 0.53.

  • China Pharma Holdings' Equity Ratio rose 850.52% to 0.53 in Q3 2025 from the same period last year, while for Sep 2025 it was 0.53, marking a year-over-year increase of 850.52%. This contributed to the annual value of 0.52 for FY2024, which is 1497.64% up from last year.
  • As of Q3 2025, China Pharma Holdings' Equity Ratio stood at 0.53, which was up 850.52% from 0.47 recorded in Q2 2025.
  • China Pharma Holdings' 5-year Equity Ratio high stood at 0.53 for Q3 2025, and its period low was 0.17 during Q3 2022.
  • Over the past 5 years, China Pharma Holdings' median Equity Ratio value was 0.38 (recorded in 2021), while the average stood at 0.38.
  • As far as peak fluctuations go, China Pharma Holdings' Equity Ratio plummeted by 5359.04% in 2022, and later surged by 12750.76% in 2023.
  • China Pharma Holdings' Equity Ratio (Quarter) stood at 0.27 in 2021, then decreased by 9.21% to 0.24 in 2022, then soared by 87.64% to 0.45 in 2023, then grew by 14.98% to 0.52 in 2024, then increased by 1.08% to 0.53 in 2025.
  • Its Equity Ratio was 0.53 in Q3 2025, compared to 0.47 in Q2 2025 and 0.49 in Q1 2025.